The recent MJBizDaily column argues that cannabis genetics are the industry’s most valuable asset. This editorial outlines what that assertion means in practical terms for breeders, seedbanks, cultivators, product developers and regulators, identifies where evidence and uncertainty sit, and sets out pragmatic priorities for stewardship, record keeping and risk management.

The Maine Office of Cannabis Policy has issued a medical‑patient advisory naming ChoicesLab dual‑chamber vape devices sold by Klouds Society. The advisory is a regulatory communication rather than a formal rule change; details published so far identify the product and seller but do not, in the original notice, set out a recall or the underlying laboratory findings. Industry actors should treat the advisory as a trigger for verification, communication and record checks while awaiting further OCP information.

MJBizDaily's recent commentary argues that genetics are the cannabis sector's most valuable, long‑lived resource. For breeders, seed banks, producers and buyers the piece is a prompt to move beyond short‑term commercial thinking: preserve provenance, manage risk from regulation and consolidation, and invest in the record‑keeping and legal tools that keep genetics usable and marketable.